RZLT - Rezolute, Inc. News

Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Exp

Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsul

Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- R

Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) has been assigned an average recommendation of "Mode

This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded NetApp, Humana, Corteva, Afya, with price-target changes for four stocks.

Lake Street Maintains Buy on Rezolute, Raises Price Target to $12

Lake Street analyst Daniel Brims maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price

Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15

Citizens analyst Jason N. Butler maintains Rezolute (NASDAQ:RZLT) with a Market Outperform and ra

This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for

FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints

Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital

Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying

Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) was the recipient of some unusual options trading ac

Rezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenita

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tu

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biolo

The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tu

Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corte

Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9

Lake Street analyst Daniel Brims initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating a

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target

Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7

Craig-Hallum analyst Albert Lowe upgrades Rezolute (NASDAQ:RZLT) from Hold to Buy and raises the

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

U.S. stocks rose as oil fell on Strait of Hormuz hopes; Benzinga highlights top analysts’ picks: OKT

HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10

HC Wainwright & Co. analyst Douglas Tsao maintains Rezolute (NASDAQ:RZLT) with a Buy and rais

Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.20) per share which missed the analyst conse

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Up

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” o

Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts

Shares of Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) have earned a consensus recommendation of

Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company

Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoin

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsul

Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoi

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” o

Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in Rezolute, Inc. (NASDAQ: RZLT) by 31.3% during the undef

MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday

Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, w

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or

Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetu

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinis

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinic

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinis

Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11

Guggenheim analyst Debjit Chattopadhyay maintains Rezolute (NASDAQ:RZLT) with a Buy and raises th

zacks.com

RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?

Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate

Rezolute To Present Four Presentations At Upcoming Annual Meeting Of Endocrine Society

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or

Maxim Group Maintains Buy on Rezolute, Raises Price Target to $14

Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the pri

Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY

Citizens Upgrades Rezolute to Market Outperform, Announces $11 Price Target

Citizens analyst Jason N. Butler upgrades Rezolute (NASDAQ:RZLT) from Market Perform to Market Ou

Wedbush Maintains Outperform on Rezolute, Raises Price Target to $6

Wedbush analyst Yun Zhong maintains Rezolute (NASDAQ:RZLT) with a Outperform and raises the price

Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stock

U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evalua

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for

HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and mai

Rezolute Reports Mid-Study Results for Rare Hypoglycemia Treatment

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperins

Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's

Maxim Group Maintains Buy on Rezolute, Raises Price Target to $10

Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the pri

Rezolute Q3 EPS $(0.16), Inline

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.16) per share which met the analyst consensu

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or

Rezolute Presents Expanded Phase 3 Data Showing Ersodetug Delivers Significant; Sees Consistent Glyc

Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrat

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patie

Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrat

Rezolute, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezol